No capacity for significant Cyp-interaction, and thus not for pharmacokinetic porphyrinogenicity. Urinary and upper respiratory tract infections are common side effects and potentially porphyrinogenic. The pharmacodynamic effects on glucose homeostasis with inhibition of pancreatic glucagon release are probably anti-porphyrinogenic.

Aminoazabiocyclohexan carbonitrile.

Saxagliptin is used in diabetes type 2 in combination with other orally administered anti-diabetics. Urinary and respiratory tract infections are common side effects and potentially porphyrinogenic. The very common hypoglycemic side effect noted in combination therapy with sulfonylureas is probably explained by enhanced effects on pancreatic insulin release and subsequent increase in tissue glucose uptake. It is thus not porphyrinogenic.

The metabolism of saxagliptin is primarily mediated by CYP 3A4/5. In in vitro studies, saxagliptin and its major metabolite neither inhibited CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1, or 3A4, nor induced CYP1A2, 2B6, 2C9, or 3A4.